Isopimpinellin inhibits Nos2/Ptgs2 inflammatory signaling to suppress macrophage M1 polarization and ameliorate DSS-induced colitis
Year: 2026
Type: article
Abstract: Introduction Disordered M1 skewed macrophage polarization and subsequent intestinal mucosal barrier failure are central pathogenic hallmarks of acute inflammatory bowel disease (IBD). Excessive pro inflammatory activation of lamina propria macrophages drives cytokine bursts and nitrosative stress, which collectively disrupt epithelial integrity and accelerate disease progression. Methods We evaluated the therapeutic efficacy of the natural furanocoumarin isopimpinellin (ISOP) using a dextran sulfate sodium (DSS)-induced colitis mouse model compared to a vehicle solvent control group, alongside in vitro primary bone marrow-derived macrophages (BMDMs). The direct pharmacological targets of ISOP were elucidated through an integrated approach utilizing quantitative proteomics, network analysis, molecular docking, and cellular thermal shift assays (CETSA). Pharmacological causality was validated via in vitro and in vivo rescue experiments using a nitric oxide (NO) donor and exogenous prostaglandin E2 (PGE2). Results and Discussion In vivo , ISOP mitigated colitic manifestations, reduced intestinal epithelial hyper permeability, preserved goblet cell associated mucin layers, restored tight junction ultrastructure and alleviated epithelial mitochondrial damage. ISOP further reshaped the colonic immune microenvironment by restraining pathological M1 macrophage infiltration, rebalancing the intestinal M1/M2 macrophage ratio, suppressing pro inflammatory cytokine release and up regulating tissue repair related anti inflammatory mediators. Integrated strategies combining quantitative proteomics, molecular docking and CETSA were adopted to screen and characterize the direct molecular targets of ISOP, while NO donor and PGE₂ rescue assays further verified its pharmacological mechanism of action. Mechanistically, ISOP negatively regulates the Nos2/Ptgs2-associated inflammatory signaling pathway by reducing iNOS (Nos2) and COX-2 (Ptgs2) protein levels, thereby suppressing M1 macrophage-derived inflammatory and nitrosative stress. Consistently, simultaneous exogenous supplementation of NO and PGE2 largely abolished ISOP derived anti inflammatory and mucosal protective effects both in vitro and in vivo. Collectively, these findings indicate that ISOP ameliorates acute colitis by restoring intestinal mucosal barrier function and normalizing macrophage immune homeostasis, supporting ISOP as a promising natural bioactive candidate for the targeted management of acute IBD.
Source: Frontiers in Immunology
Authors: Weili Yang(Conceptualization, Methodology, Writing – original draft), Longtao Zhang(Methodology, Writing – original draft), Yingying Zhang, Lu Han(Software, Writing – original draft), Yujie He(Software, Writing – original draft), Qi Ding(Software, Writing – original draft), Jiayi Sun(Software, Writing – original draft), Yu Zhang, Jinlin Cao(Software, Writing – original draft), Junli Zhou(Validation, Writing – original draft), Xihao Wang(Validation, Writing – original draft), Ju Huang(Validation, Writing – original draft), Qingqing Li(Validation, Writing – original draft), Jing Li(Conceptualization, Funding acquisition, Writing – original draft, Writing – review & editing), Zhijun Geng(Conceptualization, Funding acquisition, Writing – original draft, Writing – review & editing)
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Keywords: isopimpinellin, furocoumarins, inflammatory bowel disease, DSS-induced colitis, M1 macrophage polarization, inducible nitric oxide synthase, cyclooxygenase-2, nitric oxide, prostaglandin E2, nitrosative stress, intestinal barrier, tight junctions, goblet cells, mitochondrial damage, bone marrow-derived macrophages, natural product drug discovery
Open Access status: gold
Estimated APC paid: $3,801
OpenAlex ID: W7236734849
